An analysis of comparative effectiveness studies finds that few compare medications with nonpharmacologic interventions, and few examine safety or cost-effectiveness, according to a study in the March 10 issue of JAMA.
Comparative effectiveness (CE) research refers to studies that compare "the benefits and harms of different interventions and strategies to prevent, diagnose, treat, and monitor health conditions," according to background information in the article. In contrast to research on new interventions and strategies, CE studies help physicians use existing treatments and treatment strategies more effectively and help determine which interventions and strategies are most effective, safest, or least costly when multiple options are available.
The U.S. Congress recently passed legislation that will provide more than $1 billion to support CE studies because of concerns that insufficient research is currently devoted to improving the use of existing therapies. "Despite the recent interest in CE research, only limited information is available about existing CE studies," the authors write. "Additional information about existing CE research could help guide policy makers as they determine the amount and types of CE research that are most needed."
Michael Hochman, M.D., of the University of Southern California, Los Angeles, and Danny McCormick, M.D., M.P.H., of Harvard Medical School, Boston, examined the characteristics and prevalence of CE research concerning medications published between June 2008 and September 2009 in the six general medicine and internal medicine journals with the highest impact factors. The researchers identified 328 studies evaluating medications, 104 of which were CE studies.
Of the 104 CE studies, 43 percent compared 2 or more medications with each other, 11 percent compared medications with non-pharmacologic interventions, 31 percent compared different pharmacologic strategies, and 15 percent compared different medication doses, durations or frequencies of treatment, or different medication formulations. Nineteen percent of the CE studies focused on safety and 2 percent included cost-effectiveness analyses. Comparative effectiveness studies were less likely than non-CE studies to have been exclusively commercially funded: 13 percent vs. 45 percent. In total, noncommercial entities jointly or exclusively funded 87 percent of the CE studies, including 10 of the I1 CE studies comparing medications with nonpharmacologic interventions. Government entities at least partially funded 63 percent of the 104 CE studies.
The authors add that of 212 randomized trials, 46 percent used an active comparator (active therapy); the rest used an inactive control (such as placebo). Active-comparator trials were less likely (44 percent) than trials with inactive controls (66 percent) to report positive results.
"Overall, this study of CE research involving medications underscores the importance of the recent legislation passed in the United States to expand public funding for CE studies. In particular, our findings suggest government and noncommercial support should be increased for studies involving nonpharmacologic therapies, for studies comparing different therapeutic strategies, and for studies focusing on the comparative safety and cost of different therapies. In addition, our findings highlight the need for regulatory agencies like the FDA to require active-comparator trials for medication approval whenever feasible," the authors conclude.
(JAMA. 2010;303[10]:951-958. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Charting a Path From Comparative Effectiveness Funding to Improved Patient-Centered Health Care
In an accompanying editorial, Patrick H. Conway, M.D., M.Sc., and Carolyn Clancy, M.D., of the Department of Health and Human Services, Washington, D.C., and the Agency for Healthcare Research and Quality, Rockville, Md., write that an important question regarding these findings is how CE research will be disseminated to clinicians, patients, and others in a way that informs decisions, improves health and enhances the performance of the health care system.
###
JAMA and Archives Journals: http://www.jamamedia.org Thanks to JAMA and Archives Journals for this article.
This article has been viewed 273 time(s).
 |
 Digg |
 FarkIt |
 |
 StumbleUpon |
 del.icio.us |
 |
UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.
In Greek mythology, the gods punished Sisyphus by condemning him to roll a rock up a steep hill for eternity. But he was probably better off than if they'd condemned him to sit and stare into space until the end of time, conclude the authors of a new study on keeping busy. They found that people who have something to do, even something pointless, are happier than people who sit idly.
Public immunization efforts may be much more sensitive than previously realized to small changes in the perceived costs or risks of vaccination, scientists at Harvard University report this week. In some cases, the spread of vaccine avoidance via social networks can make the difference between a minor, localized outbreak and an epidemic four times as large.
A new study from Perth's Telethon Institute for Child Health Research shows an association between ADHD and a 'Western-style' diet in adolescents.
Stronger suction is required to smoke "electronic cigarettes" – marketed as tobacco-free nicotine delivery systems – than conventional brands, with possible adverse effects on human health, researchers at the University of California, Riverside report.
Obese older adults are more likely to use walkers, canes and other mobility devices at a younger age, and may run the risk of using them incorrectly, according to new research from Purdue University.
Heterosexual women bear the brunt of narcissistic heterosexual men's hostility, while heterosexual men, gay men and lesbian women provoke a softer reaction, according to psychologist Dr. Scott Keiller from Kent State University at Tuscarawas in the US. This is likely to be due to women's unparalleled potential for gratifying, or frustrating, men's narcissism. They are crucial players and even gatekeepers in men's quests for sexual pleasure, patriarchal power and status. Dr. Keiller's findings are published online in Springer's journal Sex Roles.
Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.